We are live on ! Find out more
NVCT icon

Nuvectis Pharma
NVCT

37 hedge funds and large institutions have $20M invested in Nuvectis Pharma in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,250% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 2

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

216% more capital invested

Capital invested by funds: $6.34M → $20M (+$13.7M)

208% more funds holding

Funds holding: 12 → 37 (+25)

4.63% more ownership

Funds ownership: 3.19% → 7.83% (+4.6%)

Holders
37
Holders Change
+25
Holders Change %
+208.33%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
8
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.8M
2
State Street
State Street
Massachusetts
+$1.47M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.24M
4
JMFC
J.M. Forbes & Co
Massachusetts
+$1.07M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
BWP
Baldwin Wealth Partners
Massachusetts
-$858K
2
Millennium Management
Millennium Management
New York
-$323K
3
Jane Street
Jane Street
New York
-$145K
4
EDRH
Edmond de Rothschild Holding
Switzerland
-$27.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$36.4K +$36.4K +2,279 New
Citigroup
27
Citigroup
New York
$32.6K +$32.5K +2,039 New
DWA
28
Dorsey Wright & Associates
California
$23.1K +$23K +1,444 New
SO
29
STRS Ohio
Ohio
$22K +$22.3K +1,400 New
Barclays
30
Barclays
United Kingdom
$21.9K +$21.9K +1,371 New
Bank of America
31
Bank of America
North Carolina
$21.7K +$19K +1,192 +727%
AB
32
Amalgamated Bank
New York
$17K +$16.6K +1,039 New
Legal & General Group
33
Legal & General Group
United Kingdom
$13.4K +$13.4K +841 New
AIP
34
Ameritas Investment Partners
Nebraska
$9.04K +$9.04K +566 New
TRCT
35
Tower Research Capital (TRC)
New York
$8.67K +$4.68K +293 +117%
MLICM
36
Metropolitan Life Insurance Company (MetLife)
New York
$6.56K +$6.56K +411 New
Fidelity Investments
37
Fidelity Investments
Massachusetts
$383 +$383 +24 New
Millennium Management
38
Millennium Management
New York
– -$323K -24,667 Closed
Jane Street
39
Jane Street
New York
– -$145K -11,086 Closed
1
2

NVCT Hedge Fund Activity: Q2 2023 in Review

37 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q2 2023, worth a combined $20M — up 216% from $6.34M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new NVCT positions and 2 closed out — a net gain of 25 holders — while 8 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $4.8M. The largest seller was Baldwin Wealth Partners, cutting an estimated $858K.

  • 37 institutional investors held Nuvectis Pharma (NVCT) as of Q2 2023, up from 12 in Q1 2023.
  • Funds reported $20M of Nuvectis Pharma stock for Q2 2023, up 216% quarter-over-quarter.
  • 27 funds opened new Nuvectis Pharma positions in Q2 2023 and 2 closed out, a net change of +25 holders.
  • The largest Nuvectis Pharma buyer in Q2 2023 was BlackRock, an estimated $4.8M added.
  • The largest Nuvectis Pharma seller in Q2 2023 was Baldwin Wealth Partners, an estimated $858K sold.

Based on aggregated 13F filings for Q2 2023.